Innate Pharma (IPHA) Stock Forecast, Price Target & Predictions
IPHA Stock Forecast
Innate Pharma stock forecast is as follows: a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
IPHA Analyst Ratings
According to 3 Wall Street analysts, Innate Pharma's rating consensus is 'Buy'. The analyst rating breakdown for IPHA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Nov 15, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Sep 16, 2022 | Citigroup | Buy | Buy | Hold |
| Aug 02, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Innate Pharma's last stock rating was published by H.C. Wainwright on Sep 13, 2024. The company gave IPHA a "Buy" rating, the same as its previous rate.
Innate Pharma Financial Forecast
Innate Pharma Revenue Forecast
| Jun 24 | Dec 23 | |
|---|---|---|
| Revenue | - | - |
| Avg Forecast | $10.30M | $16.49M |
| High Forecast | $10.30M | $16.49M |
| Low Forecast | $10.30M | $16.49M |
| # Analysts | 1 | 1 |
| Surprise % | - | - |
Innate Pharma's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IPHA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Innate Pharma EBITDA Forecast
| Jun 24 | Dec 23 | |
|---|---|---|
| # Analysts | 1 | 1 |
| EBITDA | - | - |
| Avg Forecast | $-3.25M | $-5.21M |
| High Forecast | $-3.25M | $-5.21M |
| Low Forecast | $-3.25M | $-5.21M |
| Surprise % | - | - |
undefined analysts predict IPHA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Innate Pharma's previous annual EBITDA (undefined) of $NaN.
Innate Pharma Net Income Forecast
| Jun 24 | Dec 23 | |
|---|---|---|
| # Analysts | 1 | 1 |
| Net Income | - | - |
| Avg Forecast | $-26.83M | $-32.04M |
| High Forecast | $-26.83M | $-32.04M |
| Low Forecast | $-26.83M | $-32.04M |
| Surprise % | - | - |
Innate Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IPHA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Innate Pharma SG&A Forecast
| Jun 24 | Dec 23 | |
|---|---|---|
| # Analysts | 1 | 1 |
| SG&A | - | - |
| Avg Forecast | $8.32M | $13.32M |
| High Forecast | $8.32M | $13.32M |
| Low Forecast | $8.32M | $13.32M |
| Surprise % | - | - |
Innate Pharma's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IPHA last annual SG&A of $NaN (undefined).
Innate Pharma EPS Forecast
| Jun 24 | Dec 23 | |
|---|---|---|
| # Analysts | 1 | 1 |
| EPS | - | - |
| Avg Forecast | $-0.33 | $-0.40 |
| High Forecast | $-0.33 | $-0.40 |
| Low Forecast | $-0.33 | $-0.40 |
| Surprise % | - | - |
According to undefined Wall Street analysts, Innate Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IPHA previous annual EPS of $NaN (undefined).
Innate Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| STTK | Shattuck Labs | $1.15 | $12.00 | 943.48% | Hold |
| MOLN | Molecular Partners | $5.25 | $29.00 | 452.38% | Buy |
| IPHA | Innate Pharma | $2.15 | $10.00 | 365.12% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| ADXN | Addex Therapeutics | $7.80 | $30.00 | 284.62% | Buy |